论文部分内容阅读
目的观察尤瑞克林治疗急性脑梗死的疗效及安全性。方法 2009年1月至2011年2月我科收治的急性脑梗死患者128例,随机分为尤瑞克林治疗组(n=64)和对照组(n=64),分别观察治疗前后神经功能缺损程度(NIHSS)评分,残障评分(MRS),并随访90dMRS。结果治疗后,两组患者NIHSS和MRS评分均降低(P<0.05),尤瑞克林治疗组NIHSS,MRS及总有效率均优于对照组(P<0.05),治疗组90dMRS与治疗结束相比显著降低,与对照组90dMRS相比也显著降低(P<0.01)。结论尤瑞克林治疗急性脑梗死可显著提高患者的生活质量,改善神经功能缺损状况,降低致残率,且安全性好,值得临床推广。
Objective To observe the efficacy and safety of urelin in the treatment of acute cerebral infarction. Methods 128 patients with acute cerebral infarction admitted to our department from January 2009 to February 2011 were randomly divided into two groups: norepinephrine treatment group (n = 64) and control group (n = 64). The changes of neurological function NIHSS score, disability score (MRS), and follow-up 90dMRS. Results After treatment, the scores of NIHSS and MRS were lower in both groups (P <0.05). The NIHSS, MRS and total effective rate in both groups were significantly higher than those in control group (P <0.05) (P <0.01) compared with 90 dMRS in control group. Conclusion The treatment of acute cerebral infarction with uracil can significantly improve the quality of life of patients, improve the status of neurological deficits, reduce the morbidity and safety, and is worthy of clinical promotion.